TEL AVIV, ISRAEL / ACCESSWIRE / March 12, 2018 / Elbit Imaging Ltd. ("EI" or the "Company") (TASE: EMITF; NASDAQ: EMITF) announced today (further to the disclosure in the Company's Form 20-F for the fiscal year ended December 31, 2016, under Item 3D (the caption "Risk Factors")) that the Securities and Exchange Commission ("SEC") approved an offer of settlement that was submitted to it by the Company regarding concerns of a violations of the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act of 1977 ("FCPA"), as follows:
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) development of shopping and entertainment centers in emerging markets; (ii) Medical industries and devices for: (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment; and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; and (iii) land in India designated for sale to residential projects.
For Further Information:
CEO and Chairman of the Board of Directors
SOURCE: Elbit Imaging Ltd.